The Eltrombopag Antitumor Effect on Hepatocellular Carcinoma

Overview

Journal Int J Oncol

Specialty Oncology

Date 2015 Sep 24

PMID 26397763

Citations 13

Authors

Tomohiro Kurokawa

Soichiro Murata

Yun-Wen Zheng

Kenichi Iwasaki

Keisuke Kohno

Kiyoshi Fukunaga

Nobuhiro Ohkohchi

Affiliations

Soon will be listed here.

Abstract

Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia. In these cases, sorafenib is likely effective if given in combination with treatments that increase the number of platelets, such as thrombopoietin (TPO) receptor agonists. Increasing the platelet count via TPO treatment resulted in reduction of LC. Eltrombopag (EP), a TPO receptor agonist, has been reported to have antitumor effects against certain cancers, despite their lack of TPO receptor expression. We hypothesized that EP may possess antitumor activity against HCC in addition to its ability to suppress hepatic fibrosis by increasing the platelet count. In the present study, the antitumor activity of EP was examined by assessing the inhibition of cell proliferation and then ascertaining the ability of iron supplementation to reverse these effects in HepG2, Hep3B and Huh7 cells. In addition, a cell cycle assay was performed using flow cytometry, and signal transduction was evaluated by analyzing cell cycle-related protein expression. The results of EP were compared with those of the most common iron chelator, deferoxamine (DFO). The combined effect of EP and sorafenib was also assessed. The results revealed that EP exerts antitumor activity in HCC that is mediated by the modulation of intracellular iron content. EP suppressed the expression of the cell cycle-related protein cyclin D1 and elicited cell cycle arrest in the G0/G1 phase. The activity of EP was comparable to that of DFO in HCC, and EP did not compete with sorafenib at low concentrations. In conclusion, our findings suggest that EP is a good candidate chemotherapeutic agent for the treatment of HCC in patients with LC and thrombocytopenia.

Citing Articles

Effects of genetic ablation and pharmacological inhibition of HuR on gene expression, iron metabolism, and hormone levels.

Idlin N, Krishnamoorthy S, Wolczyk M, Fakhri M, Lechowski M, Stec N BMC Biol. 2025; 23(1):24.

PMID: 39849491 PMC: 11756078. DOI: 10.1186/s12915-025-02131-z.

Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells.

Muntion S, Preciado S, Sanchez-Luis E, Corchete L, Diez-Campelo M, Osugui L Ther Adv Hematol. 2023; 13:20406207221142137.

PMID: 36601635 PMC: 9806379. DOI: 10.1177/20406207221142137.

Emerging Roles of the Iron Chelators in Inflammation.

Di Paola A, Tortora C, Argenziano M, Marrapodi M, Rossi F Int J Mol Sci. 2022; 23(14).

PMID: 35887336 PMC: 9318075. DOI: 10.3390/ijms23147977.

Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-Resistant .

She P, Li S, Zhou L, Liu Y, Xu L, Hussain Z Front Microbiol. 2022; 12:790686.

PMID: 35140693 PMC: 8819062. DOI: 10.3389/fmicb.2021.790686.

Osteosarcoma in Children: Not Only Chemotherapy.

Argenziano M, Tortora C, Pota E, Di Paola A, Di Martino M, Di Leva C Pharmaceuticals (Basel). 2021; 14(9).

PMID: 34577623 PMC: 8471047. DOI: 10.3390/ph14090923.

References

Hershko C . Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol. 1994; 7(4):965-1000. DOI: 10.1016/s0950-3536(05)80133-7. View

Peeters K, Stassen J, Collen D, Van Geet C, Freson K . Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today. 2008; 13(17-18):798-806. DOI: 10.1016/j.drudis.2008.06.002. View

Gangaidzo I, Gordeuk V . Hepatocellular carcinoma and African iron overload. Gut. 1995; 37(5):727-30. PMC: 1382882. DOI: 10.1136/gut.37.5.727. View

Wolber E, Jelkmann W . Thrombopoietin: the novel hepatic hormone. News Physiol Sci. 2002; 17:6-10. DOI: 10.1152/physiologyonline.2002.17.1.6. View

Kaplinsky C, Estrov Z, Freedman M, Gelfand E, Cohen A . Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia. 1987; 1(5):437-41. View

Fu D, Richardson D . Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood. 2007; 110(2):752-61. DOI: 10.1182/blood-2007-03-076737. View

Kaushansky K, Drachman J . The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002; 21(21):3359-67. DOI: 10.1038/sj.onc.1205323. View

Elford H, Freese M, Passamani E, MORRIS H . Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem. 1970; 245(20):5228-33. View

de Sauvage F, Luoh S, Ryan A, Dowd M, Eaton D, Moore M . Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996; 183(2):651-6. PMC: 2192470. DOI: 10.1084/jem.183.2.651. View

10.

Williams D, Peng B, Bailey C, Wire M, Deng Y, Park J . Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009; 31(4):764-76. DOI: 10.1016/j.clinthera.2009.04.010. View

11.

Erickson-Miller C, Pillarisetti K, Kirchner J, Figueroa D, Ottesen L, Martin A . Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer. 2012; 12:405. PMC: 3480928. DOI: 10.1186/1471-2407-12-405. View

12.

Kaushansky K, Broudy V, Lin N, Jorgensen M, McCarty J, Fox N . Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995; 92(8):3234-8. PMC: 42140. DOI: 10.1073/pnas.92.8.3234. View

13.

Rao V, Klein S, Agama K, Toyoda E, Adachi N, Pommier Y . The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009; 69(3):948-57. PMC: 7322628. DOI: 10.1158/0008-5472.CAN-08-1437. View

14.

Matthys G, Park J, McGuire S, Wire M, Bowen C, Williams D . Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. J Clin Pharmacol. 2010; 51(3):301-8. DOI: 10.1177/0091270010368677. View

15.

Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y . Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer. 2008; 98(3):580-6. PMC: 2243145. DOI: 10.1038/sj.bjc.6604204. View

16.

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B . Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012; 120(2):386-94. PMC: 3398759. DOI: 10.1182/blood-2011-12-399667. View

17.

Kawaguchi T, Nakano M, Satani M, Sumie S, Yamada S, Amano K . Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases. Oncol Lett. 2014; 7(6):2130-2134. PMC: 4049767. DOI: 10.3892/ol.2014.1976. View

18.

Richardson D, Baker E . The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells. Biochim Biophys Acta. 1992; 1103(2):275-80. DOI: 10.1016/0005-2736(92)90097-6. View

19.

Safonov I, Heerding D, Keenan R, Price A, Erickson-Miller C, Hopson C . New benzimidazoles as thrombopoietin receptor agonists. Bioorg Med Chem Lett. 2005; 16(5):1212-6. DOI: 10.1016/j.bmcl.2005.11.096. View

20.

Montalto G, Cervello M, Giannitrapani L, DAntona F, Terranova A, Castagnetta L . Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002; 963:13-20. DOI: 10.1111/j.1749-6632.2002.tb04090.x. View